Crizotinib is a novel FDA approved tyrosine kinase inhibitor that targets non-small-cell lung carcinoma (NSCLC) patient habouring EML4-ALK gene, meaning that molecular test for EML4-ALK is prerequisite for selecting proper patients. Aim this study is to establish an income relevant EML4-ALK screening assay. NSCLC cell line H3122, H2228, plasmid habouring different variants V1, V2, V3a, V3b, V4, VSa, VSb, V6, V7 of EML4-ALK and common molecular biology consumable stuffs. Result shown that the complex primer set named SHPT108LK-fusion was optimized that can simultaneously detect all eight different variants of EML4-ALK and did not confer any unspecific signal. This study shown that a multiplex primer PCR based assay to screen for EML4-ALK was successfully established.